The integrity of the medical information provided by New Blue Health is upheld by our rigorous Medical Review Policy. This policy ensures that every clinical claim, therapeutic description, and safety guideline published on our platform has been vetted by qualified healthcare professionals.
Our review board consists of licensed U.S. clinicians—including Medical Doctors (MDs), Nurse Practitioners (NPs), and Clinical Pharmacists—with specific expertise in endocrinology, metabolic health, and regenerative medicine.
The Review Standard
A medical review at New Blue Health is more than a simple fact-check. It is a comprehensive assessment of clinical context. Reviewers evaluate content for:
- Clinical accuracy and alignment with the latest peer-reviewed research.
- Appropriate safety framing, including the clear identification of risks and contraindications.
- Clarity in distinguishing between FDA-approved uses and emerging clinical research.
- Educational neutrality, ensuring the content does not make unsubstantiated health claims.
Conflict of Interest & Frequency
New Blue Health maintains a strict conflict of interest policy. Our medical reviewers are required to disclose any financial interests in the pharmaceutical or wellness industries that could potentially influence their clinical judgment. Reviewers are compensated for their time and expertise, but their evaluations must remain independent and evidence-based.
We review our core clinical pages at least annually. However, in the rapidly evolving landscape of peptide science, we perform ad-hoc reviews whenever major clinical trials release new data. See our Editorial Policy and Sources.